What Biorez does

Biorez is a privately held medical device company founded in 2008 and headquartered in New Haven, Connecticut, focused on developing technologies for tendon and ligament healing. The company's flagship platform is the BioBrace® Reinforced Bioinductive Implant, a soft tissue augmentation implant that combines the biological healing potential of highly porous Type I collagen with the mechanical strength of poly-L-lactic acid (PLLA) microfilaments. The dual-material architecture is engineered to share load with the repaired tendon during the vulnerable healing phase, promote new tissue ingrowth through the porous collagen scaffold, and fully resorb after approximately two years. Clinical evidence cited by the company includes a 180% increase in rotator cuff tendon thickness, up to 650 newtons of repair strength, and repair tissue reaching native-tendon-equivalent strength at 12 weeks. The implant is offered in multiple sizes (23x30mm, 40x60mm, 5x250mm) and is supported by dedicated delivery systems, including the BioBrace RC Delivery System and the Hercules XE Kit with BioBrace integration, enabling both arthroscopic and open surgical approaches across more than 70 procedures spanning rotator cuff repair, ACL reconstruction, multi-ligament knee augmentation, hip abductor repair, foot and ankle stabilization, Achilles and quadriceps tendon repair, and UCL reconstruction. The company has raised approximately $26.4 million across nine funding rounds between 2008 and 2020, with investors including Connecticut Innovations, New York Angels, LaunchCapital, The Vertical Group, Pritzker/Vlock Family Office, and Brainchild Holdings. BioBrace is commercialized and globally distributed through CONMED's direct sales force, with product listings and ordering infrastructure embedded across CONMED's orthopedic and sports medicine channels in the Americas, EMEA, and APAC. Leadership consists of Kevin Rocco as CEO and Jeffrey A. Baird as CFO; the company operates with 1-10 employees, indicating a lean organization that leverages a strategic distribution partner for commercial scale.

Name

Biorez

Website

https://biorez.com

Company type

Private

Founded year

2008

Operating status

Unknown

Headcount range

1–10 employees

Short description

Biorez is a New Haven-based medical device company developing the BioBrace Reinforced Bioinductive Implant, a Type I collagen and PLLA microfilament composite for tendon and ligament repair. The product is commercialized globally through CONMED's direct sales force to orthopedic and sports medicine surgeons across 70+ procedures.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Soft tissue implants
• Tendon repair devices
• Orthopedic implants
• Bioinductive scaffolds
• Ligament healing

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel

Distribution channels1 record

Marketing channels5 records

Core offering

Biorez develops and manufactures the BioBrace Reinforced Bioinductive Implant, a soft tissue augmentation device that combines highly porous Type I collagen with PLLA microfilaments to support tendon and ligament healing. The implant provides biomechanical load sharing during the vulnerable healing phase while promoting biological tissue regeneration, and is used across more than 70 orthopedic and sports medicine procedures including rotator cuff repair, ACL reconstruction, and foot/ankle stabilization. The product system is distributed globally through CONMED's commercial infrastructure.

Product overview

The BioBrace® Reinforced Bioinductive Implant system is a soft tissue augmentation platform designed for tendon and ligament repair across multiple anatomical sites. The core BioBrace implant combines porous Type I collagen with PLLA microfilaments for biological healing and mechanical strength. The system includes delivery systems (BioBrace®RC), surgical kits (BioBrace® Extra-Articular Kit, Hercules® XE Kit), and multiple size configurations (23x30mm, 40x60mm, 5x250mm). The implant supports approximately 70 different procedures including rotator cuff repair, ACL reconstruction, hip abductor repair, foot and ankle stabilization, and UCL repair. The product resorbs naturally over approximately 2 years after providing support during the critical healing phase.

Differentiator

Problem solved

Functional benefit

Products and services

• BioBrace Reinforced Bioinductive Implant A versatile soft tissue augmentation implant that combines the biological healing potential of highly porous Type I collagen with the mechanical strength of PLLA microfilaments to support tendon healing. Protects repairs during the vulnerable healing phase, promotes tissue growth, reduces stress on healing tissue, and naturally resorbs after approximately two years. Available in multiple sizes for orthopedic and sports medicine surgeons.
• BioBrace Extra-Articular Kit Kit designed for extra-articular ligament augmentation procedures, including MCL, LCL, PCL, PLC, and ALL/LET repairs, providing surgeons the components needed to use the BioBrace implant in these specific procedures.
• BioBrace RC Delivery System Delivery system designed for arthroscopic or open procedures to facilitate proper BioBrace implant placement, enabling accurate positioning of the implant during surgery.
• Hercules XE Kit with BioBrace Suture anchor kit that includes BioBrace integration for knotless fixation in tendon repair procedures, combining the Hercules XE knotless anchor platform with the BioBrace reinforced bioinductive scaffold.

Quantifiable outcome

• 180% increase in rotator cuff tendon thickness demonstrated in clinical evidence
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Smith & Nephew: Global medical device incumbent with REGENETEN bioinductive implant — a direct, head-to-head product to BioBrace for rotator cuff and tendon augmentation. Smith & Nephew has the sales force, clinical evidence infrastructure, and global hospital relationships that Biorez/ BioBrace must compete against.
• Stryker: Large diversified orthopedic medical device company with sports medicine, biologics, and soft tissue repair offerings overlapping with BioBrace's indications. Stryker's scale and M&A appetite make it both a competitor and a potential strategic acquirer.

Direct peers

• Arthrex: Dominant force in orthopedic sports medicine and soft tissue repair, with a broad portfolio of biologics, grafts, and suture-based augmentation products competing in many of the same 70+ procedures as BioBrace. Arthrex's private status and surgeon-loyalty model make it the most direct competitive threat.
• Integra LifeSciences:

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/biorezcompany
• LinkedInlinkedin.com/company/biorez

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biorez